TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3343-4
Abstract: PurposeThis phase I trial evaluated the safety, pharmacokinetic profile, and antitumor activity of investigational oral TORC1/2 inhibitor TAK-228 plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.MethodsSixty-seven patients received TAK-228 6–40 mg via three dosing… read more here.
Keywords: plus paclitaxel; tak 228; trastuzumab patients; without trastuzumab ... See more keywords